Immunotherapy for the Treatment of Melanoma: Module 2 of 12


It is important to note there are twelve ACI online modules, you are currently reviewing module two. You may complete any of the modules in the order you choose. Each module can be completed independently for continuing education credit. 

The Immunotherapy for the Treatment of Melanoma module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of melanoma. The module also includes case studies on immunotherapy for the treatment of melanoma.

Module 2

Marlana Orloff, MD – Thomas Jefferson University Hospital

Educational Objectives 

  • Describe clinical efficacy of approved immunotherapies
  • Recognize patient selection criteria for different immunotherapies
  • Discuss types of immunotherapies of melanoma
  • Identify factors influencing dosing and choice of immunotherapy relative to other therapies for melanoma

Target Audience

The ACI video series have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

Related Class Content

All modules offer Continuing Education (CE) Credit

Register/Access Class 

Target Audience
Clinician Icon

Credit Available
Oct. 6, 2017- Sept. 30, 2018

  • CME: 0.5 AMA PRA Category 1 Credit(s)™
  • CNE: 0.5, with 0.2 pharmacotherapy contact hours
  • CPE: 0.5 contact hours (0.05 CEUs)

Approximate Time to Complete
0.5 hours


Please use one of the following Internet browsers to open this activity: Chrome, Firefox, or Safari browsers in order to view this online activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer 

The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from 
Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.